INmune Bio, Inc. (INMB) Dr. Raymond J. Tesi, CEO

Inmune Bio is a publicly traded clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications, and Alzheimer’s. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. Dr. Raymond J. Tesi, CEO

Next Episode All Episodes Previous Episode

Listen for free

RSS Feed Apple Podcasts Spotify Pocket Casts

About the Podcast

The Wall Street Resource

Your resource for microcap discovery and due diligence

As part of the investment process, we have conducted countless CEO and executive interviews, and found this to be an invaluable use of time. We provide The Wall Street Resource, not only to help you leverage your time, but for discovery and a starting point for due diligence.

About your host

Jeffrey Kone

Managing Member and portfolio manager of a micro-cap fund for over 15 years. Securities experience that encompasses almost all aspects of the industry (buy side, sell side, retail, institutional and investment banking). Degree from University of Southern California with a Bachelor of Science in Business, emphasis in Entrepreneurship.